# US 2008/0188829 A1 · Progesterone for the treatment or prevention of spontaneous preterm birth

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188829 A1
- Document ID: US20080188829A1
- Status: Published application
- Kind: A1
- Application number: 12/024,756
- Filed: 2008-02-01
- Published: 2008-08-07
- Earliest claimed: 2007-02-06
- Inventors: George Creasy
- Web page: https://patentgrep.com/patent/US20080188829A1

## CPC

- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for treating or preventing spontaneous preterm birth in pregnant women and improving neonatal morbidity and mortality. The method includes administering to a pregnant woman in need thereof an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of her cervix. Treatment and prophylaxis with progesterone in pregnant women having symptoms of short cervix has been clinically shown to increase neonatal health.

## Claims

### Claim 1

A method for treating or preventing the onset of preterm labor and subsequent preterm birth in a pregnant woman with a short cervix comprising administering an effective amount of progesterone sufficient to prolong gestation by minimizing the shortening or effacing of the cervix.

### Claim 2 (depends on 1)

The method of claim 1, wherein the progesterone is administered as a vaginal gel.

### Claim 3 (depends on 1)

The method of claim 1, wherein the progesterone is administered as a vaginal suppository.

### Claim 4 (depends on 1)

The method of claim 1, wherein the progesterone is administered by intramuscular injection.

### Claim 5 (depends on 1)

The method of claim 1, wherein the progesterone is administered orally.

### Claim 6 (depends on 1)

The method of claim 1, wherein the progesterone is administered by rectal administration.

### Claim 7 (depends on 1)

The method of claim 1, wherein the progesterone comprises natural progesterone or a metabolite of progesterone.

### Claim 8 (depends on 1)

The method of claim 1, wherein the progesterone comprises a synthetic progesterone selected from a group consisting of 17-alpha-hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethindrone enanthate, desogestrel, levonorgestrel, lynestrenol, ethynodiol diacetate, norgestrel, norgestimate, norethynodrel, gestodene, drospirenone, trimegestone, levodesogestrel, gestodyne, nesterone, etonogestrel, and derivatives from 19-nor-testosterone.

### Claim 9 (depends on 1)

The method of claim 1, wherein the progesterone is administered daily.

### Claim 10 (depends on 9)

The method of claim 9, wherein the progesterone is administered beginning about the 18th to 22nd week of gestation until about the 37th week of gestation.

### Claim 11 (depends on 9)

The method of claim 9, wherein the progesterone is administered for about 14 to 19 weeks.

### Claim 12 (depends on 1)

The method of claim 1, wherein the amount of progesterone that is administered is between about 45 mg and 800 mg.

### Claim 13 (depends on 1)

The method of claim 1, wherein the progesterone is administered via a drug delivery system that comprises progesterone, a water-soluble, water-swellable cross-linked polycarboxylic acid polymer, and at least one adjuvant.

### Claim 14 (depends on 1)

The method of claim 1, wherein the progesterone is administered to a pregnant woman whose cervix has a length greater than about 1.0 cm.

### Claim 15 (depends on 14)

The method of claim 14, wherein the progesterone is administered to a pregnant woman whose cervix has a length between about 1.0 cm and 8.0 cm.

### Claim 16 (depends on 14)

The method of claim 14, wherein the progesterone is administered to a pregnant woman whose cervix has a length less than or equal to about 3.0 cm.

### Claim 17 (depends on 1)

The method of claim 1, wherein the progesterone comprises both natural progesterone and 17-alpha-hydroxyprogesterone.

### Claim 18 (depends on 1)

The method of claim 1, wherein the progesterone is administered by a delivery device configured for insertion into the vagina.

### Claim 19 (depends on 18)

The method of claim 18, wherein the delivery device comprises a cervical ring.

### Claim 20 (depends on 9)

The method of claim 9, wherein the progesterone is administered beginning about the 16th week of gestation until about the 37th week of gestation.

### Claim 21 (depends on 9)

The method of claim 9, wherein the progesterone is administered for about 21 weeks.

### Claim 22 (depends on 9)

The method of claim 9, wherein the progesterone is administered beginning about the time of a positive pregnancy test until about the 37th week of gestation.

### Claim 23 (depends on 9)

The method of claim 9, wherein the progesterone is administered beginning about the 2nd to 4th week of gestation.

### Claim 24 (depends on 9)

The method of claim 9, wherein the progesterone is administered for about 33 to 35 weeks.

### Claim 25 (depends on 9)

The method of claim 9, wherein the progesterone is administered depending on the gestational age at the beginning of treatment and the date of delivery.

### Claim 26 (depends on 12)

The method of claim 12, wherein the amount of progesterone that is administered is about 90 mg and the progesterone is natural progesterone administered vaginally.

### Claim 27 (depends on 1)

The method of claim 1, wherein the progesterone is administered as a vaginal cream.

### Claim 28 (depends on 1)

The method of claim 1, wherein the progesterone is administered as a vaginal solid dosage form.

### Claim 29

A method of improving neonatal morbidity and mortality in a preterm neonate comprising:
administering to a pregnant woman symptomatic of a shortened or an effaced cervix in need thereof an effective amount of progesterone sufficient to maintain and/or delay a further shortening of cervical length or sufficient to prolong gestation.

### Claim 30 (depends on 29)

The method of claim 29, wherein the progesterone is administered using one or more forms selected from the following group: a vaginal gel, a vaginal suppository, vaginal drug delivery device, vaginal cream, and other vaginal pharmaceutical application.

### Claim 31 (depends on 29)

The method of claim 29, wherein the progesterone is adapted for oral, subcutaneous, rectal, vaginal, intradermal, topical, intranasal, intramuscular, intraperitoneal, intraarticular, intraventricular, intrathecal, intravaginal, or intravenous administration.

### Claim 32 (depends on 29)

The method of claim 29, wherein the progesterone comprises natural progesterone or a metabolite of progesterone.

### Claim 33 (depends on 29)

The method of claim 29, wherein the progesterone comprises a synthetic progesterone selected from a group consisting of 17-alpha-hydroxyprogesterone caproate, medroxyprogesterone acetate, norethindrone, norethindrone acetate, norethindrone enanthate, desogestrel, levonorgestrel, lynestrenol, ethynodiol diacetate, norgestrel, norgestimate, norethynodrel, gestodene, drospirenone, trimegestone, levodesogestrel, gestodyne, nesterone, etonogestrel, and derivatives from 19-nor-testosterone.

### Claim 34 (depends on 29)

The method of claim 29, wherein the progesterone is administered daily.

### Claim 35 (depends on 34)

The method of claim 34, wherein the progesterone is administered beginning about the 18th to 22nd week of gestation until about the 37th week of gestation.

### Claim 36 (depends on 34)

The method of claim 34, wherein the progesterone is administered for about 14 to 19 weeks.

### Claim 37 (depends on 29)

The method of claim 29, wherein the amount of progesterone that is administered is between about 45 mg and 800 mg.

### Claim 38 (depends on 29)

The method of claim 29, wherein the progesterone is administered via a drug delivery system that comprises progesterone, a water-soluble, water-swellable cross-linked polycarboxylic acid polymer, and at least one adjuvant.

### Claim 39 (depends on 29)

The method of claim 29, wherein the progesterone is administered to a pregnant woman whose cervix has a length greater than about 1.0 cm.

### Claim 40 (depends on 39)

The method of claim 39, wherein the progesterone is administered to a pregnant woman whose cervix has a length between about 1.0 cm and 8.0 cm.

### Claim 41 (depends on 39)

The method of claim 39, wherein the progesterone is administered to a pregnant woman whose cervix has a length less than or equal to about 3.0 cm.

### Claim 42 (depends on 29)

The method of claim 29, wherein the progesterone comprises both natural progesterone and 17-alpha-hydroxyprogesterone.

### Claim 43 (depends on 29)

The method of claim 29, wherein the progesterone is administered by a delivery device configured for insertion into the vagina.

### Claim 44 (depends on 29)

The method of claim 29, wherein the progesterone is administered in combination with one or more compounds for the treatment or prophylaxis of preterm birth.

### Claim 45 (depends on 29)

The method of claim 29, wherein the progesterone is administered in combination with a clinical procedure for the treatment or prophylaxis of preterm birth.
